Thursday, February 7, 2019
1:00 p.m. – 2:00 p.m. ET
The U.S. capital markets remain an attractive source of capital for emerging companies in the life sciences sector. Over 21.7% of the 2017 IPOs were life sciences companies. Many of these IPOs were preceded by late stage (or mezzanine) private placements made principally to U.S. institutional investors.
In our session, partners Anna Pinedo and David Bakst will focus on:
- Financing alternatives for pre-IPO companies;
- The late-stage (or “cross-over”) private placement market;
- Considering milestones when planning a financing strategy; and
- Post-IPO alternatives, including registered direct offerings, PIPE transactions, at the market offerings, and related financing considerations
To register, please click here.